Article Text

Download PDFPDF

Original research
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells
  1. Mittal Shah1,2,
  2. Asher Maroof1,
  3. Panos Gikas3,
  4. Gayatri Mittal3,
  5. Richard Keen3,
  6. Dominique Baeten1,
  7. Stevan Shaw1 and
  8. Scott J Roberts1,2,4
  1. 1 UCB Pharma, Slough, UK
  2. 2 Division of Surgery and Interventional Science, University College London, London, UK
  3. 3 Royal National Orthopaedic Hospital Stanmore, Stanmore, UK
  4. 4 Department of Comparative Biomedical Sciences, Royal Veterinary College, London, UK
  1. Correspondence to Dr Scott J Roberts; scott.roberts{at}ucl.ac.uk

Abstract

Objectives Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understood. This study aimed to investigate IL-17 signalling in the context of pathological bone formation.

Methods A biomimetic human periosteum-derived cell (hPDC) model of osteogenic differentiation was used in combination with recombinant IL-17 cytokines, T-cell supernatants or serum from patients with AS. IL-17A, IL-17F and bimekizumab monoclonal antibodies were used to block IL-17 cytokine action.

Results Recombinant IL-17A and IL-17F are pro-osteogenic with respect to hPDC differentiation. T helper 17 or γδ-T cell supernatants also potently stimulated in vitro bone formation, which was blocked deeper by dual inhibition of IL-17A and IL-17F than by neutralisation of IL-17A or IL-17F individually. Osteogenic blockade may be due to an increase in expression of the Wnt antagonist DKK1. Interestingly, osteocommitment was also induced by serum obtained from patients with AS, which was also abrogated by dual neutralisation of IL-17A and IL-17F.

Conclusions These data show for the first time that IL-17A and IL-17F enhance in vitro osteogenic differentiation and bone formation from hPDCs, inhibition of which may offer an attractive therapeutic strategy to prevent pathological bone formation.

  • TCells
  • Cytokines
  • Ankylosing Spondylitis
  • Inflammation
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors MS, SR, RK and SS contributed to the conception and design of the study. MS and AM were involved in the acquisition of data. PG, GM and RK provided scientific/clinical interpretation and patient material/data acquisition. MS, AM, DB, SS and SR contributed to the analysis and interpretation of data. SR supervised the study. All authors contributed to drafting and/or revising the manuscript.

  • Funding This work was funded by UCB Pharma.

  • Competing interests MS, AM, SS and DB are employees of UCB Pharma. PG has received honoraria from Medacta International. RK has received honoraria from Kyowa Kirin, Amgen and Clementia Pharmaceuticals, and consulting fees from Kyowa Kirin and Clementia Pharmaceuticals. SR is a former employee of UCB Pharma and has received consulting fees from Angitia Biopharmaceuticals.

  • Patient consent for publication Not required.

  • Ethics approval This study was approved by the NHS Research Ethics Committee (research authority: Yorkshire and the Humber—Leeds West Research Ethics Committee 16/YH/0137).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.